表紙
市場調查報告書

全球搭配診斷(CDx)市場 - 產業分析與市場預測(2017年∼2022年)

Companion Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 390597
出版日期 內容資訊 英文 118 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球搭配診斷(CDx)市場 - 產業分析與市場預測(2017年∼2022年) Companion Diagnostics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年02月01日內容資訊: 英文 118 Pages
簡介

全球搭配診斷(CDx)市場,2014年價值45億美元,至2020年預計以35%的年複合成長率成長到270億美元。

本報告提供全球搭配診斷(CDx)市場相關調查,市場概要,各指標、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 報告的說明
  • 調查方法

第2章 搭配診斷市場概要

  • 簡介
    • 情境和背景
    • 體外診斷和搭配診斷的差異
    • 標籤相關考慮事項
    • 傳統的藥品&體外診斷的發展
    • 法律規範

第3章 全球搭配診斷市場趨勢

  • 市場成長要素
    • 新藥和診斷企業的成長
    • 癌症發病率的上升
    • 藥物的安全性/有效性概況的改善
    • 藥物開發成本的增加
    • 藥品核准流程的加速
  • 市場阻礙因素
    • 複雜的臨床試驗的實施
    • 智慧財產權的問題
    • 償付制度的問題
  • 市場機會
    • 研究投資
    • 新藥的突破
    • 更短的開發時間軸
    • 市場滲透的進展

第4章 全球搭配診斷市場:各指標

  • 市場概要
  • 肺癌
  • 乳癌
  • 大腸癌
  • 黑色素瘤
  • 白血病
  • 其他(腦瘤、胃癌、前列腺癌)

第5章 全球搭配診斷市場:各地區

  • 市場概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第6章 市場佔有率分析

  • 主要企業的市場佔有率
  • 各市場區隔的主要企業

第7章 競爭情形

  • 新產品的創新
  • 協定,合作,合資企業,聯盟
  • 合併和收購
  • 法規機關

第8章 企業簡介

  • A&G Pharmaceutical, Inc.
  • Abbott Diagnostics
  • Biocrates Life Sciences AG
  • Clovis Oncology, Inc.
  • Dako A/S
  • EKF Diagnostics Holdings plc.
  • Eli Lilly and Company
  • Eutropics Pharmaceuticals, Inc.
  • Daan Diagnostics Ltd.
  • Foundation Medicine, Inc.
  • Genentech, Inc.
  • Intezyne, Inc.
  • Leica Biosystems GmbH
  • Myriad Genetics, Inc.
  • NEOMICS Co., Ltd.
  • NuCana Biomed Limited
  • Oxford Biodynamics Limited
  • Qiagen NV
  • Roche Diagnostics Limited
  • Siemens Healthcare Diagnostics Inc.
  • Skuldtech France
  • 武田藥品工業
  • TheraDiag SA
  • Thermo Fisher Scientific Inc.
  • Tocagen Inc.
  • Ventana Medical Systems, Inc.

第9章 附錄

  • 簡稱
  • 參考資料
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 51372

Market Overview

The growth of the global companion diagnostics market can be attributed to the rising focus on personalized medicine and co-development of drug and diagnostic technologies. In addition, rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. One of the major factors driving the growth of the companion diagnostics market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics, in order to focus on cost regulations, there has been significant number of opportunities for its applications in indications, like cancer, cardiovascular and neurological disorders, etc.

Scope of the Report

Companion diagnostic tests provide information that is essential for the safe and effective use of a corresponding drug or biological product. As per the scope of the report, the market studied has been segmented by technology, indications, and geography. By technology, the market studied has been further segmented into immunohistochemistry, polymerase chain reaction, in-situ hybridization, real time-polymerase chain reaction, gene sequencing, and other technologies.

Key Market Trends

In-situ Hybridization (ISH) Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

In-situ hybridization (ISH), especially fluorescence in-situ hybridization (FISH), is a reliable, reproducible, sensitive, and accurate procedure, which is less affected by tissue fixation and analytical variables, in comparison to immunochemistry and other techniques. It offers the benefit of simultaneous evaluation of morphology and gene amplification. FISH has been the method of choice for use in companion diagnostics for several cancer therapies, such as trastuzumab, lapatinib, and criotinib, which have been already approved by FDA and other therapies, like everolimus, ridaforolimus, bicatulamide, TBD, and other drugs, that are yet to obtain regulatory approval.

The global market for in-situ hybridization in CDx is growing because of technological advancements, like the recent development of bright-field in-situ hybridization techniques, chromogenic in-situ hybridization (CISH), and the automated silver-enhanced in-situ hybridization (SISH) for the determination of gene status. Thus, considering the aforementioned factors, the ISH segment is expected to exhibit growth over the forecast period.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall companion diagnostics market, with the United States emerging as the major contributor to the market. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, which is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostic assays are classified as IVD class III products, which represents a high-risk category, and consequently, the highest level of regulatory control. Hence, owing to high healthcare technology adoption rates and increasing demand for personalized medicine, the market for companion diagnostics in the United States is expected to register a substantial growth rate during the forecast period.

Competitive Landscape

The presence of major market players, such as Abbott, Agilent Technologies, F. Hoffmann-La Roche Ltd, Biomerieux SA, and Qiagen NV, is, in turn, increasing the overall competitive rivalry of the market. But the issues associated with the high development cost and poor reimbursement are affecting the market negatively. However, the rising focus of companies toward personalized medicine, co-development activities, and increased cases of adverse drug reactions is expected to boost the competitive rivalry in the market studied.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option
    • 4.2.2 Increasing Cases of Adverse Drug Reactions
    • 4.2.3 Co-development of Drug and Diagnostic Technology
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Drug Development and Associated Clinical Trials
    • 4.3.2 Reimbursement Issues among Many Countries
  • 4.4 Industry Attractiveness- Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Immunohistochemistry (IHC)
    • 5.1.2 Polymerase Chain Reaction (PCR)
    • 5.1.3 In-situ Hybridization (ISH)
    • 5.1.4 Real-time PCR (RT-PCR)
    • 5.1.5 Gene Sequencing
    • 5.1.6 Other Technologies
  • 5.2 By Indication
    • 5.2.1 Lung Cancer
    • 5.2.2 Breast Cancer
    • 5.2.3 Colorectal Cancer
    • 5.2.4 Leukemia
    • 5.2.5 Melanoma
    • 5.2.6 Other Indications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Agilent Technologies Inc.
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Biomerieux SA
    • 6.1.5 Qiagen NV
    • 6.1.6 Siemens Healthcare
    • 6.1.7 Thermo Fisher Scientific Inc.
    • 6.1.8 Danaher Corporation (Beckman Coulter Inc.)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top